Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Masonic Cancer Center, University of Minnesota

420 Delaware Street SE, Minneapolis, MN 55455

The Masonic Cancer Center was founded in 1991 as the University of Minnesota Cancer Center and received its NCI designation in 1998. It was renamed the Masonic Cancer Center (MCC) in 2009. The Center combines population sciences, basic research, and translational cancer care with community outreach and educational activities. The Center facilitates the research of its members, fosters multidisciplinary approaches to cancer, provides infrastructure support for cancer research, and develops new methods and strategies to reduce cancer incidence and mortality.

Prevention, screening, new therapies, biomarker evaluation, functional imaging of cancer, and cancer survivorship are the themes of the work conducted by MCC’s 500+ research members. The major research programs are: Carcinogenesis and Chemoprevention, Cellular Mechanisms, Genetic Mechanisms of Cancer, Immunology; Screening, Prevention, Etiology, and Cancer Survivorship; and Transplant Biology and Therapy.

The Center’s clinical research and treatment partners include M Health Fairview and the M Health Fairview University of Minnesota Masonic Children’s Hospital. The Center’s research partners include the University’s Stem Cell Institute, the Center for Immunology, the Center for Magnetic Resonance Imaging, and the Institute of Human Genetics.

Specific scientific strengths of MCC include: chemoprevention and carcinogenesis, particularly in tobacco; obesity prevention research; hematopoietic stem cell biology and transplantation, especially in hematologic malignancies; translational research in immune and cell-based therapies; childhood malignancies, including biology, therapy, epidemiology, and survivorship; cancer prevention and screening, especially in colorectal and other solid tumors; immunology; novel mouse models to study cancer center etiology and progression; functional magnetic resonance imaging in cancer; and the development of interventional strategies for cancer prevention and treatment.

The Center also takes a leadership role in mission, community interactions, outreach, public relations, and advocacy. Education and outreach programs in the community include involvement with the Minnesota Cancer Alliance/Cancer Plan Minnesota. MCC has also followed up its research in the area of tobacco with an outreach program to advance understanding of tobacco use, addiction, and harm reduction.

Website: cancer.umn.edu

Trials at this location:

HCRN GU14-182

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182

Status: Closed to Accrual
Read More

HCRN MEL16-252

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252

Status: Closed to Accrual
Read More